Showing 341 - 360 results of 114,475 for search '(( 5 ((026 decrease) OR (a decrease)) ) OR ( a ((non decrease) OR (nn decrease)) ))', query time: 1.34s Refine Results
  1. 341

    DataSheet1_Treatment of wild-type mice with 2,3-butanediol, a urinary biomarker of Fmo5−/− mice, decreases plasma cholesterol and epididymal fat deposition.PDF by Sunil Veeravalli (5074115)

    Published 2022
    “…Our results indicate a microbial contribution to the phenotypic characteristic of Fmo5<sup>−/−</sup> mice of decreased plasma cholesterol and identify 2,3-butanediol as a potential agent for lowering plasma cholesterol.…”
  2. 342
  3. 343
  4. 344
  5. 345

    Antagonizing BMP type I receptors decreases cell growth, proliferation, and clonogenicity of lung cancer cell lines. by Elaine Langenfeld (402034)

    Published 2013
    “…<p>(<b>A</b>) A549 and H1299 cells cultured in DMEM 5% FCS were treated with DMSO, 10 µM Dorsomorphin, 1 µM DMH1, 1 µM DMH2, or 1 µM LDN for 7 days and cell counts performed. …”
  6. 346
  7. 347
  8. 348
  9. 349
  10. 350
  11. 351
  12. 352
  13. 353

    Relationships between empty body lipid weight decrease and corrected amounts of pollutants excreted through faeces (faecal output–feed input) for TCDD (○, ●), and PCBs 153 (□, ■) and 126 (Δ, ▲) over a 57-day depuration period in ewes receiving a control well-fed and non-supplemented treatments (CTL: ○, □, Δ; <i>n</i> = 4), or an underfed and mineral oil supplemented treatment (UFMO: ●, ■, ▲; <i>n</i> = 5). by Sylvain Lerch (1494349)

    Published 2020
    “…<p>Relationships between empty body lipid weight decrease and corrected amounts of pollutants excreted through faeces (faecal output–feed input) for TCDD (○, ●), and PCBs 153 (□, ■) and 126 (Δ, ▲) over a 57-day depuration period in ewes receiving a control well-fed and non-supplemented treatments (CTL: ○, □, Δ; <i>n</i> = 4), or an underfed and mineral oil supplemented treatment (UFMO: ●, ■, ▲; <i>n</i> = 5).…”
  14. 354
  15. 355
  16. 356
  17. 357
  18. 358
  19. 359
  20. 360

    Investigating the shared genetics of non-syndromic cleft lip/palate and facial morphology by Laurence J. Howe (5579186)

    Published 2018
    “…Where evidence was found of genetic overlap, we used bidirectional Mendelian randomization (MR) to test the hypothesis that genetic liability to nsCL/P is causally related to implicated facial phenotypes. Across 5,804 individuals of European ancestry from two studies, we found strong evidence, using PRS, of genetic overlap between nsCL/P and philtrum width; a 1 S.D. increase in nsCL/P PRS was associated with a 0.10 mm decrease in philtrum width (95% C.I. 0.054, 0.146; P = 2x10<sup>-5</sup>). …”